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cardial effusion, cardiac tamponr
ade, congestive heart failure, and 
sinus bradycardia have previously 
been reported as complications of 
cytosine arabinoside.1r3 Fludarabine 
is a purine antagonist that is comr
monly used for patients with nonr
Hodgkin lymphoma and chronic 
lymphocytic leukemia. The most 
common adverse effects are myelor
suppression and immunosuppresr
sion. Cardiovascular complications 
of fludarabine are rare, although 
several cases of congestive heart 
failure or left ventricular failure 
have been reported.4r5 
There are many possible etir
ologies for the bradycardia seen in 
the present patient. For example, 
sepsis, cardiogenic events, electror
lyte imbalance, and drugs such as 
cytosine arabinoside may all cause 
bradycardia. An adverse drug reacr
tion is considered to be the probr
able cause of the bradycardia in this 
patient because no other etiologies 
were apparent. Cytosine arabinor
side seemed an unlikely cause of 
bradycardia because the patient 
had received cytosine arabinosider
containing chemotherapy previousr
ly. The bradycardia occurred during 
fludarabine treatment and subsided 
significantly after completion of the 
infusion of this drug. Other probr
able causes of bradycardia had alr
ready been excluded and therefore 
it is reasonable to speculate about 
a possible relationship between 
fludarabine and the sinus bradyr
cardia observed in this patient. 
Clinicians should be aware of this 
potential toxic effect of fludarabine, 
especially in view of its increased 
use in the treatment of hematologic 
diseases. 
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To the Editor: One of the most 
important causes of morbidity 
and mortality after hematopoietic 
stem cell transplantation (HSCT) 
is bronchiolitis obliterans (BO), 
which sometimes leads to irreversr
ible and progressive air flow obr
struction (AFO).1r3 Usually this 
complication is seen after alloger
neic transplantation in up to 26% of 
cases.4 The usual diagnostic method 
is spirometry. Other modalities are 
high resolution computed tomograr
phy (HRCT) and lung biopsy. The 
most well known and consistent 
risk factor for BO is chronic graftr
versusrhost disease (GVHD).4,5
This crossrsectional study was 
carried out at the Shariati Hospital, 
Hematology, Oncology and Stem 
Cell Transplantation Research 
Center to compare diagnostic 
methods and to determine addir
tional risk factors by two diagnostic 
methods. The patients who had alr
logeneic HSCTs at least six months 
previously were included in the 
study and followed from January to 
June 2009. Exclusion criteria were 
current smoking or a history of 
smoking, history of asthma, chronic 
obstructive pulmonary disease or 
bronchiectasis, transplantation 
more than one time and abnormal 
spirometry with an FEV1/FVC less 
than 70%. All of the patients underr
went spirometry and chest HRCT 
in the inspiratory and expiratory 
phase. Spirometric criteria for dir
agnosis of bronchiolitis obliterans 
without consideration of the age of 
the patient is defined as FEV1/FVC 
less than 75% or a more than 10% 
decrement of FEV1/FVC from the 
baseline value. HRCT criteria were 
air trapping or a mosaic pattern, 
which is exaggerated on expiratory 
views. A diagnosis of bronchiolitis 
obliterans requires one of the spiror
metric or imaging criteria.
Fortyrtwo patients completed 
the study. Nineteen (45.2%) met 
the diagnostic criteria for BO, but 
only 11 (26.2%) had abnormal spir
rometry and 17 (40.5%) patients 
had air trapping and a mosaic patr
tern in the chest HRCT that was 
compatible with a diagnosis of BO. 
Eleven (26.2%) patients had a hisr
tory of acute GVHD and 21 (50%) 
had a history of chronic GVHD. 
Only 10 (23.8%) had no history 
of acute or chronic GVHD. There 
was a statistically meaningful corr
relation between BO and GVHD 
(P=.037); only one case of BO was 
in the nonrGVHD group (10%), 
6 cases in the acute GVHD group 
(54.5%) and 12 cases were in the 
chronic GVHD group (57.1%). 
Ten patients (23.8%) were less than 
20 years old, 22 were in the 21r40 
yearrold group (52.4%) and 10 par
tients (23.8%) were older than 41 
years.
This article is reprint a that was 
originally published in the Annals 
of Saudi Medicine 2010;30(3):246r
247.
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Patient age seemed an indepenr
dent risk factor for BO because 
the age range of 21r40 years had 
a 22.6 times greater chance of der
veloping BO than those patients 
younger than 20 years old (odds 
ratio=22.6, 95% CI: 1.8r277.9 
P=.015) and the older group (41r
60 years) had a 16.6 times risk of 
developing BO compared with 
youngest group (OR=16.6, 95% 
CI: 1.1r246.8, P=.041).
Donorrrecipient was a risk 
factor for BO (P=.037). More 
BO was seen in male recipients 
with female donors, which was 
expected, but interestingly the 
negative predictive value of sympr
toms (cough, sputum, dyspnea) in 
the age group under 20 years was 
100%, compared with 80% in the 
middle group and 75% in the oldr
est group, which indicates that 
patients under 20 years old need 
screening for BO if they are asr
ymptomatic. The second point we 
want emphasize is that spirometry 
is used for diagnosis of BO alone 
in most studies. The correlation of 
the two diagnostic methods in this 
study was 48%, but HRCT had a 
better diagnostic yield alone and 
fewer patients will be missed when 
screening by this method. 
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